Abstract
Cost utility analysis and trials including patient-centred outcomes are required to evaluate the use of PLEX. Furthermore, ascertaining those at high risk of developing ESRF could help identify those who may benefit from PLEX the most, and further insights are required in setting of diffuse alveolar haemorrhage.
Original language | English |
---|---|
Pages (from-to) | 111-117 |
Number of pages | 7 |
Journal | Current Rheumatology Reports |
Volume | 24 |
Issue number | 4 |
Early online date | 22 Mar 2022 |
DOIs | |
Publication status | Published - Apr 2022 |
Keywords
- ANCA-associated vasculitis
- Diffuse alveolar haemorrhage
- End-stage renal failure
- Plasma exchange